In this article, we will look at the 10 Best Strong Buy Stocks to Buy Under $10.
On July 29, Michael Arone, State Street chief investment strategist, appeared on CNBC’s ‘Power Lunch’ to talk about the ongoing market rally and why nothing is stopping it.
He stated that there are a couple of factors behind this, including an improvement in trade, as more trade deals continue to be announced. He expects free cash flow windfall from the one big beautiful bill to also be a tailwind for many companies, especially those that spend considerable amounts of money on R&D.
Dollar weakness is another factor he cited, as more than 40% of the S&P 500 revenues come from outside the US, making it a tailwind, especially for tech companies.
READ ALSO: 10 Most Undervalued Blue Chip Stocks to Buy According to Hedge Funds and 11 Most Oversold Energy Stocks To Buy Right Now.
Despite lofty valuations, Arone expects the market rally to continue. An increase in trade deals, earnings growth, and AI spending is anticipated to push stocks even higher. The strategist also stated that he favors technology, communication services, industrials, and financials.
With these trends in view, let’s look at the best strong buy stocks to invest in under $10.
A business executive examining a financial index chart, illustrating the company’s involvement in the global stock market.
Our Methodology
We used Finviz and Tipranks to make a list of strong buy stocks with a stock price under $10 and selected the top 10 with consensus Strong Buy ratings and the highest number of hedge fund holders as of Q1 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database, and also added the analyst upside potential for each stock. The list is sorted in ascending order of hedge fund holders.
Note: All data was sourced on July 29.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10 Best Strong Buy Stocks to Buy Under $10
10. Denison Mines Corp. (NYSE:DNN)
Stock Price: $2.10
Analyst Upside: 30.53%
Number of Hedge Fund Holders: 23
Denison Mines Corp. (NYSE:DNN) is one of the best strong buy stocks to buy under $10. On July 18, Raymond James raised the firm’s price target on Denison Mines Corp. (NYSE:DNN) to C$3.80 from C$3.70, keeping an Outperform rating on the shares.
The rating update came after Denison Mines Corp. (NYSE:DNN) announced on July 16 the discovery of additional high-grade mineralization “around 40 meters outside of the previously estimated mineralized domain associated with the D1 lens of the Gryphon uranium deposit”.
Management reported that the discovery was a part of the successful delineation drill program carried out at Gryphon during the first half of 2025. Results from the delineation drilling program are anticipated to bolster confidence for the previously projected mineral resources for Gryphon.
Denison Mines Corp. (NYSE:DNN) is involved in the exploration and development of uranium. The company holds interests in the Athabasca Basin, Wheeler River, Midwest Project, McClean Lake, and Waterbury Lake.
9. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Stock Price: $8.11
Analyst Upside: 48.06%
Number of Hedge Fund Holders: 30
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best strong buy stocks to buy under $10. In a report released on July 25, Les Sulewski from Truist Financial maintained a Buy rating on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) with a price target of $8.00.
The rating update followed Amneal Pharmaceuticals, Inc.’s (NASDAQ:AMRX) announcement of certain unaudited preliminary financial results for fiscal Q2 on July 21. The company has plans to report the actual Q2 2025 results on August 5.
The unaudited preliminary financial results for the quarter showed a net revenue of $720 million to $730 million, suggesting an increase of around 3% versus the same period last year. Adjusted EBITDA rose around 13% to $180 million to $185 million, with income before income taxes of $45 million to $56 million, compared to $20 million in the same period in 2024.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is a medicine company that provides pharmaceuticals. The company’s product portfolio encompasses biosciences, specialty, generics, and product catalog. Its operations are divided into the Generics, Specialty, and AvKARE segments.
8. NexGen Energy Ltd. (NYSE:NXE)
Stock Price: $7.13
Analyst Upside: 31.38%
Number of Hedge Fund Holders: 33
NexGen Energy Ltd. (NYSE:NXE) is one of the best strong buy stocks to buy under $10. In a report released on June 12, Colin McLelland from Petra Capital maintained a Buy rating on NexGen Energy Ltd. (NYSE:NXE) with a price target of A$10.80.
In other news, NexGen Energy Ltd. (NYSE:NXE) announced on June 12 that the Saskatchewan Ministry of Environment granted approval for NexGen Energy Ltd.’s (NYSE:NXE) 2025 Site Program at its 100%-owned Rook I Property in the Athabasca Basin, Saskatchewan.
Management reported that the program entails the establishment of a temporary exploration airstrip, site access road improvements, and an expansion of the exploration accommodation camp facilities by 373 beds. The program is set to conclude with camp commissioning in Q1 2026.
NexGen Energy Ltd. (NYSE:NXE) acquires, explores, and develops uranium properties. Headquartered in Vancouver, Canada, the company’s uranium project portfolio encompasses Arrow, South Arrow, Harpoon, Bow, IsoEnergy, SW1, SW2, SW3, and IsoEnergy properties.
7. VNET Group, Inc. (NASDAQ:VNET)
Stock Price: $8.27
Analyst Upside: 46.76%
Number of Hedge Fund Holders: 34
VNET Group, Inc. (NASDAQ:VNET) is one of the best strong buy stocks to buy under $10. On June 30, Citi analyst Louis Tsang reiterated their bullish stance on VNET Group, Inc. (NASDAQ:VNET), giving it a Buy rating with a $20 price target.
The analyst based the rating on VNET Group, Inc.’s (NASDAQ:VNET) promising growth prospects, stating that the company raised its revenue and EBITDA guidance for fiscal year 2025, suggesting solid financial performance and aligning with the analyst’s above-consensus projections.
Tsang also stated that VNET Group, Inc.’s (NASDAQ:VNET) $50 million share repurchase program is anticipated to bolster the stock price, while updates on initiatives like the B30 project, H-share IPO, and C-REIT potentially leading to further re-rating.
VNET Group, Inc. (NASDAQ:VNET) is a carrier and cloud-neutral internet data center services provider in China. The company provides hosting and related services, including cloud services, IDC services, and business VPN services to support the security, reliability, and speed of the internet infrastructure of its customers.
6. Hudbay Minerals Inc. (NYSE:HBM)
Stock Price: $9.88
Analyst Upside: 28.34%
Number of Hedge Fund Holders: 34
Hudbay Minerals Inc. (NYSE:HBM) is one of the best strong buy stocks to buy under $10. On July 22, Stifel analyst Ralph Profiti raised the firm’s price target on Hudbay Minerals Inc. (NYSE:HBM) to C$17 from C$16.50, keeping a Buy rating on the shares.
Hudbay Minerals Inc. (NYSE:HBM) reported $594.9 million in revenue in its fiscal Q1 2025 results, along with a record quarterly adjusted EBITDA of $287.2 million.
The strong results were attributed to record-low consolidated cash cost performance, as all three of the company’s business units executed on their planned strategies and expanded operating cost margins.
Hudbay Minerals Inc. (NYSE:HBM) also reported consolidated copper production of 30,958 tonnes in Q1 2025, in line with the quarterly cadence expectations. However, consolidated gold production for the quarter exceeded the quarterly cadence expectations at 73,784 ounces. This solid performance was driven by outperformance in Manitoba.
Hudbay Minerals Inc. (NYSE:HBM) is a mining company that produces copper concentrate, molybdenum concentrate, and zinc metal. The company’s focus is on the production, discovery, and marketing of base and precious metals.
5. TeraWulf Inc. (NASDAQ:WULF)
Stock Price: $5.24
Analyst Upside: 35.00%
Number of Hedge Fund Holders: 35
TeraWulf Inc. (NASDAQ:WULF) is one of the best strong buy stocks to buy under $10. In a report released on July 24, Ed Engel from Compass Point maintained a Buy rating on TeraWulf Inc. (NASDAQ:WULF) with a price target of $6.50.
On May 27, TeraWulf Inc. (NASDAQ:WULF) announced the acquisition of 100% of the membership interests of Beowulf Electricity & Data LLC and its affiliates, collectively known as “Beowulf E&D”.
Management stated that the strategic transaction simplifies TeraWulf Inc.’s (NASDAQ:WULF) corporate structure and also “eliminates a related-party relationship consolidating resources under a unified operating framework”.
TeraWulf Inc. (NASDAQ:WULF) operates and owns data center infrastructure specifically designed for high-performance computing and Bitcoin mining. It primarily leverages environmentally sustainable and zero-carbon energy sources, such as hydroelectric and nuclear power, to power its Bitcoin mining and other operations.
4. Payoneer Global Inc. (NASDAQ:PAYO)
Stock Price: $6.68
Analyst Upside: 26.11%
Number of Hedge Fund Holders: 38
Payoneer Global Inc. (NASDAQ:PAYO) is one of the best strong buy stocks to buy under $10. Deutsche Bank analyst Nate Svensson resumed coverage of Payoneer Global Inc. (NASDAQ:PAYO) with a Buy rating on July 16, setting a price target of $8.00.
Payoneer Global Inc. (NASDAQ:PAYO) reported growth in its fiscal Q1 2025 results, with revenue growing 16% year-over-year, excluding interest income. This growth was attributed to a notable take rate expansion with SMB customers and 7% volume growth.
ARPU excluding interest income for the quarter also rose 22%, marking the seventh consecutive quarter of growth. Management attributed these positive trends to growth in higher take rate B2B, continued strength among larger customers, Checkout and Card franchises, and various pricing initiatives.
Payoneer Global Inc. (NASDAQ:PAYO) also reported an 18% year-over-year increase in SMB customer revenue in fiscal Q1 2025, reaching $170 million.
Payoneer Global Inc. (NASDAQ:PAYO) is a financial technology company that provides a financial platform for medium and small-sized businesses to conduct transactions and do business. Headquartered in New York, NY, the company’s operations are divided into the Israel, United States, and All Other Countries geographical segments.
3. Coeur Mining, Inc. (NYSE:CDE)
Stock Price: $9.12
Analyst Upside: 31.73%
Number of Hedge Fund Holders: 38
Coeur Mining, Inc. (NYSE:CDE) is one of the best strong buy stocks to buy under $10. In a report released on July 7, Michael Siperco from RBC Capital maintained a Buy rating on Coeur Mining, Inc. (NYSE:CDE), setting a price target of $11.00.
On May 27, Coeur Mining, Inc. (NYSE:CDE) announced that its Board of Directors authorized a $75 million share repurchase program effective through May 31, 2026.
Mitchell J. Krebs, Chairman, President and Chief Executive Officer, stated that the share repurchase program aims to enhance the per-share value for Coeur Mining, Inc.’s (NYSE:CDE) shareholders.
He added that the initiative suggests management’s confidence in the company’s strong free cash flow profile, attributed to increased gold and silver prices, continued momentum at the expanded Rochester mine, impact of the Las Chispas mine, and consistent performance from its other three operations.
Krebs also stated that after a number of years of heavy investment, Coeur Mining, Inc. (NYSE:CDE) is now in a position “to continue rapidly paying down debt, maintain the pace of reinvestment in high-return organic growth opportunities, while beginning to return capital to shareholders.”
Coeur Mining, Inc. (NYSE:CDE) explores and develops gold and silver mines and mining properties in the US, Canada, and Mexico. It operates through the Palmarejo, Rochester, Kensington, Wharf, and Other segments. The Palmarejo segment manages a gold-silver complex, while the Rochester segment operates a silver-gold mine in northwestern Nevada. Similarly, the Kensington and Wharf segments operate an underground gold mine and an open-pit heap leach gold mine, respectively.
2. Alight Inc. (NYSE:ALIT)
Stock Price: $5.51
Analyst Upside: 74.15%
Number of Hedge Fund Holders: 41
Alight Inc. (NYSE:ALIT) is one of the best strong buy stocks to buy under $10. On May 9, Wedbush lowered the firm’s price target on Alight Inc. (NYSE:ALIT) to $9 from $11, keeping an Outperform rating on the shares.
The firm told investors in a research note that Alight Inc. (NYSE:ALIT) had a strong start to 2025 with its Q1 2025 results, reporting a beat on the top line and meeting Wall Street expectations on the bottom line.
It added that Alight Inc. (NYSE:ALIT) is continually experiencing traction in its recurring revenue streams across its customer base. The company’s client-centric focus is resonating soundly, paving the way for new and expanded wins, according to the firm.
While Wedbush acknowledged that a complicated macro backdrop may lead to elongated client decision-making, it believes that Alight Inc. (NYSE:ALIT) is well-positioned to take strategic steps to attain its mid-term targets and deliver essential solutions for clients to bring costs down across operations.
Headquartered in Chicago, IL, Alight Inc. (NYSE:ALIT) provides cloud-based integrated digital human capital and business solutions.
1. Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Stock Price: $6.12
Analyst Upside: 154.57%
Number of Hedge Fund Holders: 47
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best strong buy stocks to buy under $10. In a report released on July 15, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) with a price target of $13.00.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported $125.2 million in total revenues for fiscal Q1 2025, representing a 15% operational growth measured at constant exchange rates (CER) and a currency headwind of $1.4 million or 1%.
The company has cash, cash equivalents, and marketable securities totaling $250.6 million as of March 31, 2025, reflecting minute growth as compared to $249.9 million at December 31, 2024.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotech company that discovers, develops, and delivers medicines to treat metabolic diseases. Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
While we acknowledge the potential of FOLD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than FOLD and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
